Ramsay Santé: Frédéric Collet tipped for chairmanship following RHC's exit
The governance changes announced on 16 November 2026 by Ramsay Santé are part of the preparation for the in-kind distribution, by Ramsay Health Care Limited (RHC), of its 52.79% stake to its own shareholders. They would take effect upon completion of this distribution, currently expected on 9 December 2026.
A former president of Novartis France tipped to chair the board
The Board of Directors intends to appoint Frédéric Collet as independent Chairman upon completion of the distribution, subject to his appointment as a director by the General Meeting of 4 December 2026 and completion of the transaction. He would then resign from the Mission Committee of Ramsay Santé, on which he sits.
Frédéric Collet joined Novartis in 2005 and chaired Novartis France from 2017 to 2022, as well as LEEM, the professional organization of pharmaceutical companies, from 2019 to 2022. Since 2023, he has been founder and president of Bionnassay-Consult and senior advisor at Eurazeo.
Five new directors proposed, freeing up as many RHC board seats
At this meeting, shareholders will also be asked to approve the appointment as directors of Pascal Roché, Group Chief Executive Officer, Alexandra Boleslawski, Virginie Banet, Alexandre de Palmas and Fredrik Reinfeldt. In parallel, the five directors appointed on the proposal of RHC will resign upon completion of the distribution.
Alexandra Boleslawski was Group Chief Risk Officer of Crédit Agricole from 2019 to 2025, Alexandre de Palmas is Chief Executive Officer of Carrefour France, and Fredrik Reinfeldt is a former Prime Minister of Sweden. Virginie Banet, for her part, has spent more than 25 years in finance.
The board would then comprise eleven directors, including two employee representatives. Excluding the latter, 5 of 9 members would be independent (55.6%), and the board would include 4 women (44.4%) and 5 men (55.6%), in line with applicable regulations and the recommendations of the Afep-Medef Code.
According to the group, this structure would combine an independent chairmanship with continuity of executive management during the implementation of the "Connecting Care 2030" strategic plan, presented at the Investor Day in September 2026.
The transaction remains subject to approval by RHC shareholders at their General Meeting scheduled for 24 November 2026, and to obtaining the required authorizations.